Champions Oncology (CSBR) vs OKYO Pharma (OKYO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Champions Oncology (CSBR) has outperformed OKYO Pharma (OKYO) over the past year, losing 35.9% versus a loss of 49.5%. Champions Oncology is the larger company by market cap ($60.4 million vs $56.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CSBR | OKYO |
|---|---|---|
| Share price | $4.34 | $1.07 |
| Market cap | $60.41M | $56.15M |
| 1-day change | -1.36% | -7.76% |
| YTD return | -37.19% | -48.31% |
| 1-year return | -35.89% | -49.53% |
| 5-year return | -52.98% | — |
| Forward P/E | 43.40 | — |
| EPS (TTM) | $-0.07 | $-0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $59.42M | — |
| Revenue growth (YoY) | +4.36% | — |
| Net income (latest FY) | $-1.18M | $-4.71M |
| Gross margin | 48.00% | — |
| Operating margin | -1.92% | — |
| Net margin | -1.98% | — |
| 52-week high | $8.31 | $3.20 |
| 52-week low | $4.34 | $1.00 |
| Distance from 52-week high | -47.77% | -66.56% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +678.50% |
| Average volume | 9.71K | 143.41K |
| Shares outstanding | 13.92M | 52.48M |
| Employees | 214 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CSBR has outperformed OKYO by 13.6 percentage points over the past year.
About Champions Oncology
CSBR stock →Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 214 employees
About OKYO Pharma
OKYO stock →OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees
CSBR vs OKYO FAQ
Which is bigger, Champions Oncology or OKYO Pharma?
Champions Oncology (CSBR) is larger, with a market capitalization of $60.41M compared with $56.15M for OKYO Pharma (OKYO).
Which stock has performed better over the past year, CSBR or OKYO?
CSBR returned -35.89% over the past 12 months, compared with -49.53% for OKYO (price return, excluding dividends). Past performance does not predict future results.
Are Champions Oncology and OKYO Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.